Drug therapy for CPPD in real clinical practice
- 24 June 2026
- journal article
- Published by Alfmed LLC in Medical alphabet
- No. 12
Abstract
According to the recommendations of the ELUAR expert committee, the choice of drug therapy for calcium pyrophosphate deposition disease (CPPD) is based on the clinical presentation (phenotype) of the disease. However, it is unknown whether this approach is implemented in real clinical practice. The aim of the study was to analyze the frequency of use of drugs prescribed for the treatment of CPPD in various phenotypes of the disease. Materials and methods . A total of 266 patients with CPPD over 18 years of age with clinical symptoms were examined. These patients were divided into phenotypes: recurrent acute arthritis, chronic arthritis, and osteoarthritis (OA) with calcium pyrophosphate (CPP) crystals. The frequency of prescription of colchicine, methotrexate, hydroxychloroquine, glucocorticoids (GCs), and nonsteroidal anti-inflammatory drugs (NSAIDs) was compared. Results . Based on phenotyping results, the group of patients with acute arthritis consisted of 40 patients (15 %), chronic arthritis – 157 (59 %), and OA with PFK crystals – 69 (26 %). The frequency of medications used to treat CPPD in all study participants (n=266): 207 patients (77.8 %) received NSAIDs, 97 (36.5 %) colchicine, 46 (17.3 %) hydroxychloroquine, 60 (22.6 %) methotrexate, and 34 (12.8 %) GCs. In acute arthritis, 30 patients (75 %) received NSAIDs, 5 (12.5 %) GCs, 17 (42.5 %) colchicine, 4 (10 %) hydroxychloroquine, and 8 (20 %) methotrexate. Patients with chronic arthritis: 123 (78.3 %) NSAIDs, 21 (13.4 %) – GCs, 58 (36.9 %) – colchicine, 29 (18.5 %) – hydroxychloroquine, 40 (25.5 %) – methotrexate. Patients with OA with CPP crystals: 54 (78.3 %) – NSAIDs, 8 (11.6 %) – GCs, 22 (31.9 %) – colchicine, 13 (18.8 %) – hydroxychloroquine, 12 (17.4 %) – methotrexate. Conclusions . The most commonly used medications for CPPD are NSAIDs and colchicine, with no significant differences in the frequency of prescription of individual medications across different disease phenotypes. The use of low-dose colchicine in CPPD appears to be the most appropriate.Keywords
This publication has 16 references indexed in Scilit:
- The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease: a systematic review and meta-analysisEuropean Journal of Preventive Cardiology, 2025
- Pseudogout, chondrocalcinosis, CPPD et al: crystal clear… or clear as mud?–The time has come to reconsider the nomenclature of calcium pyrophosphate depositionAnnals of the Rheumatic Diseases, 2025
- Describing calcium pyrophosphate deposition: undoing the tower of Babel!Current Opinion in Rheumatology, 2024
- Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trialThe Lancet Rheumatology, 2023
- Pathogenesis of calcium pyrophosphate deposition diseaseBest Practice & Research Clinical Rheumatology, 2021
- Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine, 2020
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and KneeArthritis Care & Research, 2020
- European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosisAnnals of the Rheumatic Diseases, 2011
- EULAR recommendations for calcium pyrophosphate deposition. Part II: ManagementAnnals of the Rheumatic Diseases, 2011
- OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidenceOsteoarthritis and Cartilage, 2007